Atypical development of behavioural sensitization to 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy') in adolescent rats and its expression in adulthood: Role of the MDMA chirality

Addiction Biology

Volumn 15, Issue 1, 2010, Pages 35-44

  Von Ameln, Nora ^a   Von Ameln Mayerhofer, Andreas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Adolescence; Habituation; Locomotion; R MDMA; S MDMA; Sensitization

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG EFFECT; HABITUATION; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION;

3,4-DIHYDROXYPHENYLACETIC ACID; AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; HALLUCINOGENS; HYDROXYINDOLEACETIC ACID; MALE; MICE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; STEREOISOMERISM; STREET DRUGS;

EID: 71949120621     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2009.00187.x     Document Type: Article

References (49)

1. Alves E, Summavielle T, Alves CJ, Custodio JB, Fernandes E, de Lourdes Bastos M, Tavares MA, Carvalho M (2009) Ecstasy-induced oxidative stress to adolescent rat brain mitochondria in vivo: influence of monoamine oxidase type A. Addict Biol 14 : 185 193.
2. Anagnostaras SG, Robinson TE (1996) Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behav Neurosci 110 : 1397 1414.
3. Baker LE, Taylor MM (1997) Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Pharmacol Biochem Behav 57 : 737 748.
4. Baker TB, Tiffany ST (1985) Morphine tolerance as habituation. Psychol Rev 92 : 78 108.
5. Battaglia G, De Souza EB (1989) Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr 94 : 240 258.
6. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988) Pharmacologic profile of MDMA (3,4-Ethylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149 : 159 163.
7. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987) 3,4-methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242 : 911 916.
8. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ (1999) Stereospecific analysis and enantiomeric disposition of 3, 4- methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 45 : 1058 1069.
9. Fantegrossi WE (2007) Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? Psychopharmacology (Berl) 189 : 471 482.
10. Fantegrossi WE, Murai N, Mathúna BO, Pizarro N, de la Torre R (2009) Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J Pharmacol Exp Ther 329 : 1006 1015.
11. Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G (2002) 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology (Berl) 161 : 356 364.
12. Glennon RA (2000) Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Pharmacol Biochem Behav 64 : 251 256.
13. Gold LH, Hubner CB, Koob GF (1989) A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology (Berl) 99 : 40 47.
14. Heffner TG, Hartman JA, Seiden LS (1980) A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav 13 : 453 456.
15. Hiramatsu M, Cho AK (1990) Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29 : 269 275.
16. Hiramatsu M, Nabeshima T, Kameyama T, Maeda Y, Cho AK (1989) The effect of optical isomers of 3,4-methylenedioxymethamphetamine (MDMA) on stereotyped behavior in rats. Pharmacol Biochem Behav 33 : 343 347.
17. Johnson MP, Hoffman AJ, Nichols DE (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132 : 269 276.
18. Kalivas PW, Duffy P, White SR (1998) MDMA elicits behavioural and neurochemical sensitization in rats. Neuropsychopharmacology 18 : 469 479.
19. Lebsanft HB, Kohles T, Kovar KA, Schmidt WJ (2005) 3,4- methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy. Synapse 55 : 148 155.
20. Leussis MP, Bolivar VJ (2006) Habituation in rodents: a review of behavior, neurobiology, and genetics. Neurosci Biobehav Rev 30 : 1045 1064.
21. Liechti ME, Baumann CH, Gamma A, Vollenweider FX (2000a) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22 : 513 521.
22. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000b) Psychological and physiological effects of MDMA ('Ecstasy') after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23 : 396 404.
23. Liechti ME, Vollenweider FX (2000) Acute psychological and physiological effects of MDMA ('Ecstasy') after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10 : 289 295.
24. Lyon RA, Glennon RA, Titeler M (1986) 3,4-methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology (Berl) 88 : 525 526.
25. Mayerhofer A, Schmidt WJ (2000) Development of sensitisation of behavioural effects of 3,4-methylenedioxymethamphetamine (MDMA). Eur J Neurosci 12 (Suppl. 5 411.
26. Mayerhofer A, Kovar KA, Schmidt WJ (2001) Changes in serotonin, dopamine and noradrenaline levels in striatum and nucleus accumbens after repeated administration of the abused drug MDMA in rats. Neurosci Lett 308 : 99 102.
27. McCann UD, Eligulashvili V, Ricaurte GA (2000 +/-)3,4- methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42 : 11 16.
28. 1B/1D receptors. J Pharmacol Exp Ther 290 : 965 973.
29. McKenna DJ, Guan XM, Shulgin AT (1991) 3,4-methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5- hydroxytryptamine. Pharmacol Biochem Behav 38 : 505 512.
30. Meyer A, Mayerhofer A, Kovar K-A, Schmidt WJ (2002a) Rewarding effects of the optical isomers of 3,4-methylenedioxy- methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats. Neurosci Lett 330 : 280 284.
31. Meyer A, Mayerhofer A, Kovar K-A, Schmidt WJ (2002b) Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine ('Ecstasy') and 3,4-methylenedioxyethylamphetamine ('Eve') isomers in rat brain and blood. Neurosci Lett 330 : 193 197.
32. Meyer MR, Maurer HH (2009) Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation. Chem Res Toxicol 22 : 1205 1211.
33. Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 152 : 230 248.
34. Nash JF (1990) Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci 47 : 2401 2408.
35. Piper BJ (2007) A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol 29 : 288 300.
36. Piper BJ, Vu HL, Safain MG, Oliver AJ, Meyer JS (2006) Repeated adolescent MDMA exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther 317 : 838 849.
37. Pizarro N, Farré M, Pujadas M, Peiró AM, Roset PN, Joglar J, de la Torre R (2004) Stereochemical analysis of 3,4- methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab Dispos 32 : 1001 1007.
38. Ramos M, Goni-Allo B, Aguirre N (2005) Ibotenic acid lesions of the medial prefrontal cortex block the development and expression of 3,4-methylenedioxymethamphetamine-induced behavioral sensitization in rats. Behav Brain Res 160 : 304 311.
39. Ricaurte GA, Yuan J, McCann UD (2000 +/-)3,4- methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42 : 5 10.
40. Robinson TE, Becker JB (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396 : 157 198.
41. Robinson TE, Berridge KC (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18 : 247 291.
42. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Therap 240 : 1 7.
43. Shulgin AT (1986) The background and chemistry of MDMA. J Psychoactive Drugs 18 : 291 304.
44. Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behaviour in the rat. Pharmacol Biochem Behav 32 : 835 840.
45. Spitzer M, Franke B, Walter H, Buechler J, Wunderlich AP, Schwab M, Kovar KA, Hermle L, Grön G (2001) Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans. Neuropharmacology 41 : 263 271.
46. Sprague JE, Everman SL, Nichols DE (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19 : 427 442.
47. Stewart J, Badiani A (1993) Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 4 : 289 312.
48. Verrico CD, Miller GM, Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189 : 489 503.
49. Wiley JL, Evans RL, Grainger DB, Nicholson KL (2008) Age-dependent differences in sensitivity and sensitization to cannabinoids and 'club drugs' in male adolescent and adult rats. Addict Biol 13 : 277 286.